Guidelines for Parkinson’s disease management part II - consensus from the movement disorders scientiﬁc department of the Brazilian Academy of Neurology - non-motor symptoms

Sep 29, 2026

Uploaded by Logic

Parkinson’s disease management is presented as highly individualized, requiring tailored recommendations for Brazilian practice. The Brazilian Academy of Neurology (ABN) developed guidance for treating non-motor symptoms through a specialist panel in movement disorders. Building on a prior article focused on motor symptoms, this part targets neuropsychiatric problems such as depression, anxiety, cognitive changes, and psychosis, and also addresses pain, sleep disorders, and dysautonomia with recommended therapies and medications.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Introduction

Non-motor symptoms targeted by the guideline

Scope and relationship to the motor-symptoms part

Background: individualized treatment and ABN evidence adaptation

Article published online: 2025-02-24 Brazilian Academy of Neurology 1 Guidelines for Parkinson’s disease management part II: consensus from the movement disorders scientiﬁc department of the Brazilian Academy of Neurology – non-motor symptoms Débora Palma Maia 1 Rubens Gisbert Cury2 Pedro Renato P. Brandão3,4,5 Francisco E. C. Cardoso6 Ana Paula Bertholo7 André Carvalho Felicio8 Arlete Hilbig9,10 Bruno Lopes Santos Lobato 11 Eline Rozária F. Barbosa5 Elizabeth Maria A. B. Quagliato 11 Gustavo H. C. Sousa 12 Jacy Bezerra Parmera7 Márcia Rúbia7 Marcus Vinícius Della Coletta 13 Maria Sheila Guimarães Rocha 14 Mariana Spitz 15 Mônica Haddad7 Nina Rosa A. F. Murta 1 Paulo Caramelli6 Raimundo N. D. Rodrigues 16 Ricardo Nitrini7 Roberto Prado 17 Vitor Tumas 18 Ylmar Corrêa Neto 19 Roberta Arb Saba20,21 1 Universidade Federal de Minas Gerais, Hospital das Clínicas, Departamento de Neurologia, Belo Horizonte MG, Brazil. 2 Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Centro de Distúrbios do Movimento, São Paulo SP, Brazil. 3 Hospital Sírio Libanês, Brasília DF, Brazil. 4 Universidade de Brasília, Hospital da Universidade de Brasília, Brasília DF, Brazil. 5 Clínica Neurológica, Departamento de Saúde, Congresso Nacional, Brasília DF, Brazil. 6 Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica/Neurologia, Belo Horizonte MG, Brazil. 7 Universidade de São Paulo, Hospital das Clínicas, Departamento de Neurologia, São Paulo SP, Brazil. 8 Hospital Israelita Albert Einstein, São Paulo SP, Brazil. 9 Hospital São José, Porto Alegre RS, Brazil. 10 Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre RS, Brazil. 11 Universidade Federal do Pará, Laboratório de Neuropatologia Experimental, Belém PA, Brazil. Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962 . Address for correspondence Débora Palma Maia ([email: maiadp@icloud.com](email: maiadp@icloud.com)) 12 Hospital de Base do Distrito Federal, Brasília DF, Brazil. 13 Universidade do Estado do Amazonas, Departamento de Neurologia, Escola Superior de Ciências da Saúde, Manaus AM, Brazil. 14 Hospital Santa Marcelina, São Paulo SP, Brazil. 15 Universidade do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brazil. 16 Unidade de Sono de Brasília, Brasília DF, Brazil. 17 Universidade Federal de Sergipe, Faculdade de Medicina, Aracaju SE, Brazil. 18 Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurologia, Ribeirão Preto SP, Brazil. 19 Universidade Federal de Santa Catarina, Faculdade de Medicina, Departamento de Neurologia, Florianópolis SC, Brazil. 20 Universidade Federal de São Paulo, Departamento de Neurologia, Setor de Transtornos do Movimento, São Paulo SP, Brazil. 21 Hospital do Servidor Público Estadual de São Paulo, Serviço de Neurologia, Setor de Transtornos do Movimento, São Paulo SP, Brazil. Abstract Keywords ► Parkinson Disease ► Dementia ► Autonomic Nervous System Diseases ► Pain The treatment of Parkinson’s disease (PD) is a challenge, especially because it is considered highly individualized. The Brazilian Academy of Neurology (ABN) hasidentiﬁed the need to disseminate knowledge about its management, adapting the best evidence to the Brazilian population. The present article aims to report the recommendations for the treatment of non-motor symptoms of PD, developed by a group of specialists in movement disorders from the ABN ’s scientiﬁc department. In 2021, the ﬁrst part, referring to the motor symptoms of PD, was published. The main non-motor symptoms were addressed—among them neuropsychiatric symptoms, such received August 5, 2024 received in its ﬁnal form October 10, 2024 accepted October 10, 2024 DOI [https://doi.org/](https://doi.org/)[ ](https://doi.org/)10.1055/s-0045-1802962 . ISSN 0004-282X Editor-in-Chief: Hélio A. G. Teive. Associate Editor: Rena

FAQs

What is the purpose of this Parkinson’s disease guideline part II?

It reports specialist recommendations for treating Parkinson’s disease non-motor symptoms in line with Brazilian needs and adapted evidence.

How is this article connected to the earlier motor-symptoms guideline?

It complements the first part published in 2022, which focused on motor symptoms, while this part focuses on non-motor symptoms.

Which non-motor symptom areas does the guideline cover?

It addresses neuropsychiatric symptoms such as depression, anxiety, cognitive alterations, and psychosis, as well as treatments for pain, sleep disorders, and dysautonomia.

Sep 29, 2026

Uploaded by Logic